Dihydropyrimidine dehydrogenase (DPD) and pyrimidine nucleoside phosphorylase (PyNPase) are the first and rate-limiting enzymes that regulate 5-fluorouracil (5-FU) metabolism, and tumoral DPD activity appears to be a promising predictor of 5-FU sensitivity. However, the regulatory mechanisms determining these enzyme activities have not been fully understood. We investigated the biological effects of epidermal growth factor (EGF) and transforming growth factor (TGF)-α α α α Key words: Dihydropyrimidine dehydrogenase -Pyrimidine nucleoside phosphorylase -Growth factor -5-Fluorouracil sensitivity -Cervical cancer 5-Fluorouracil (5-FU) has been widely used in the treatment of a variety of neoplastic diseases, particularly cancers of the breast and digestive organs, and is given either alone or in combination with other cytostatics. We have demonstrated that 5-FU-based chemotherapy is also useful for the treatment of uterine cervical cancer.
5-Fluorouracil (5-FU) has been widely used in the treatment of a variety of neoplastic diseases, particularly cancers of the breast and digestive organs, and is given either alone or in combination with other cytostatics. We have demonstrated that 5-FU-based chemotherapy is also useful for the treatment of uterine cervical cancer. 1, 2) Two main modes of action have been proposed for 5-FU through its active metabolites, 5-fluoro-dUMP (FdUMP) and 5-fluoro-UTP. FdUMP suppresses thymidylate synthetase (TS) by forming a covalent ternary complex with 5,10-methylenetetrahydrofolate, which inhibits DNA synthesis.
3) 5-Fluoro-UTP is incorporated into cellular RNA, resulting in RNA dysfunction. 4) 5-FU is initially anabolized by pyrimidine nucleoside phosphorylase (PyNPase) in both pathways. Thymidine phosphorylase (ThdPase) converts 5-FU to 5-fluorodeoxyuridine (FUdR), a precursor of FdUMP. Uridine phosphorylase (UrdPase) converts 5-FU to 5-fluorouridine (FUR), a precursor of 5-fluoro-UMP, which is finally metabolized to 5-fluoro-UTP. The former enzyme is identical to platelet-derived endothelial cell growth factor (PD-ECGF) 5) and is closely associated with tumor angiogenesis. 5, 6) 5-FU is initially catabolized to 5-fluorodihydrouracil (DHFU) by dihydropyrimidine dehydrogenase (DPD), mainly in the liver, then dihydropyrimidinase and β-ureido-propionase catalyze the formation of 2-fluoro-β-alanine. Several recent studies [7] [8] [9] [10] concerned with 5-FU antitumor effects have demonstrated that tumoral DPD activity may influence 5-FU sensitivity. Thus, DPD and PyNPase are considered to be the first and rate-limiting enzymes in the chain of reactions that regulate 5-FU metabolism.
Determination of tumoral DPD has become of clinical interest because elevated intratumoral DPD can influence the tumor response to 5-FU therapy as a result of increased inactivation. Etienne et al. 8) evaluated DPD activity in tumor biopsy specimens from head and neck cancer patients before administration of 5-FU and found that the tumoral/non-tumoral DPD activity ratio was higher in the non-responding patients than in those with a partial or complete response. Moreover, certain biochemical modulations to enhance the antitumor activity of 5-FU by inhibiting intratumoral DPD activity have been attempted. 11, 12) The underlying differences in tumoral DPD activity result in a variable 5-FU degradation prior to 5-FU engagement in the anabolic pathway and therefore affect the 5-FU sensitivity of the tumor. However, it is still unclear why DPD activity varies within an individual tumor and what factors intrinsically regulate its intratumoral activity.
Inflammatory cytokines, tumor necrosis factor α (TNF α), interleukin-1α (IL-1α) and interferon γ (INF γ), which are often detected in the tumor environment, 13) are reported to upregulate PyNPase expression in human and mouse tumor cells and to increase the sensitivity of tumor cells to 5′-deoxy-5-fluoro-uridine (5′-dFUrd), which is biotransformed into 5-FU by PyNPase.
14, 15) Eda et al. 14) indicated that growth factors, such as PD-ECGF and basic fibroblast growth factor, might also be involved in the biochemical modulation of the anti-proliferative activity of 5-FU and 5′-dFUrd. Ishikawa et al. 15) demonstrated that some cytokines simultaneously upregulate the potential of Lewis lung carcinoma cells to invade extracellular matrices and their PyNPase activity, modulating the specific action of 5′-dFUrd to selectively kill tumor cells with high invasive and metastatic potential. We have also reported that epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), which are secreted by tumor cells and/or surrounding interstitial cells, stimulate invasive activity and proteinase expression of gynecological tumor cells. 16, 17) These reports led us to examine whether tumor environmental factors affect the rate-limiting enzyme activity in 5-FU metabolism, which may regulate the antiproliferative action of 5-FU in an individual tumor. In the present study, we investigated the biological effects of EGF and TGF-α on cell growth and tumoral DPD and PyNPase activities, and the effects on 5-FU sensitivity of tumor cells.
MATERIALS AND METHODS
Cell culture SKG-IIIb, 18) originating from a moderately differentiated epidermoid carcinoma of the uterine cervix, was kindly provided by Dr. S. Nozawa (Keio University School of Medicine, Tokyo). SKG-IIIb cells possess EGF receptors with a dissociation constant of 8.3 nM, and the total binding sites amount to 164 fmol/mg protein, as previously described.
16) The cells were maintained as monolayer cultures in Ham's F-12 nutrient mixture (Gibco, Paisley, UK) supplemented with heat-inactivated 10% fetal bovine serum (Gibco) at 37°C in a humidified incubator with 5% CO 2 . They were grown to confluence in 25-cm 2 tissue-culture flasks (Nunc, Roskilde, Denmark), washed with phosphate-buffered saline (PBS), and then harvested after a brief treatment with 0.1% trypsin solution containing 0.02% EDTA (Gibco). The cell viability was determined by Trypan-blue-dye exclusion prior to use. MTT assay Effects of EGF and TGF-α on the proliferation of SKG-IIIb cells were examined by means of MTT assay with some modifications, as previously described. 19) Cells (5×10 3 ) in a volume of 100 µl of growth medium per well were uniformly seeded into 96-well microplates (Corning, New York, NY) and incubated at 37°C for 24 h. The medium was then replaced with 100 µl of serum-free medium containing various amounts of growth factors. After further incubation at 37°C for 24, 48, and 96 h, 10 µl of MTT dissolved in PBS at a concentration of 5 mg/ ml was added to each well, and the plates were incubated at 37°C for 4 h. The medium was removed, 150 µl of dimethyl sulfoxide was added to each well, and the plates were agitated for 5 min. The absorbance was then read at 570 nm in a scanning spectrophotometer (Molecular Devices Co., Sunnyvale, CA). In a parallel experiment, the effects of EGF and TGF-α on the antiproliferative action of 5-FU on SKG-IIIb cells were examined. We previously observed that 0.1 to 100 µg/ml of 5-FU with EGF or TGF-α had cytotoxic effects on SKG-IIIb cells. 20) Therefore, for this further investigation, cells were exposed to serum-free medium containing lower concentrations of 5-FU (0.001 to 0.1 µg/ml) 24 h after plating to confirm the biological effects of these growth factors at achievable therapeutic levels of 5-FU. The cells were cultured at 37°C for 7 days in the presence or absence of growth factors, and cell viability was evaluated by MTT assay. Results are expressed as the relative percentage of absorbance compared to controls. DPD assay DPD activity was measured according to the method described by Beck et al. 7) with some modifications. Aliquots (6×10 6 ) of tumor cells in 60 ml of conditioned medium were seeded in a flask and incubated at 37°C for 24 h. The medium was then replaced with the same volume of serum-free medium containing various amounts of growth factors. After further incubation at 37°C with or without growth factors for 24, 48, and 96 h, the cells were harvested, washed with PBS, collected by centrifugation, and stored at −80°C until use. The cell pellet was freeze-thawed twice and centrifuged at 15 000 rpm for 30 min at 4°C. The supernatant was kept on ice until assayed. The assay consisted of incubating 500 µl of supernatant with 100 µl of 5-[ 
21)
PyNPase assay PyNPase activity was assayed according to the method reported by Horiuchi et al. 22) with some modifications. Twenty-four hours after seeding, cells were exposed to various amounts of growth factors for 24, 48, and 96 h. The cells were then harvested, washed with PBS, collected by centrifugation, and stored at −80°C as described above. The cell pellet was sonicated for 15 min on ice in 1 ml of 50 mM potassium phosphate buffer (pH 7.4) containing 12.5 mM 2-mercaptoethanol. This solution was then centrifuged at 105 000g for 60 min at 4°C. One milliliter of the supernatant was gradually mixed with 1.222 ml of saturated ammonium sulfate, kept on ice for 30 min, and centrifuged at 14 000g for 15 min at 4°C. The precipitate was then dissolved in 1 ml of 20 mM Tris-HCl buffer (pH 7.4) containing 5 mM 2-mercaptoethanol, dialyzed for 16 h at 6°C, and used as a source of enzyme assay. The reaction mixture for ThdPase assay contained 100 µl of 180 mM Tris-HCl buffer (pH 7.4), 50 µl of 30 mM 5-FU, 50 µl of 30 mM deoxyribose-1-phosphate, and 100 µl of the enzyme solution from the cells. The reaction was carried out at 37°C for 15 min and was then terminated by the addition of 70 µl of 3 M HClO 4 . The reaction mixture for UrdPase assay contained 100 µl of 180 mM Tris-HCl buffer (pH 7.4), 50 µl of 6 mM 5-FU, 50 µl of 6 mM ribose-1-phosphate, and 100 µl of the enzyme solution from the cells. The reaction was done at 37°C for 45 min and was terminated as described above. The sample was then mixed with 50 µl of 0.22 mM 3-methylxanthine as the internal standard. After centrifugation at 15 000 rpm for 30 min at 4°C, 50 µl of the supernatant was added to an HPLC column (YMC-ODS-AM302), and the amount of FUdR or FUR produced was measured with a UV monitor at 269 nm. Statistical analysis All experiments were performed in triplicate. The significance of differences between groups was calculated by applying a non-parametric test. The Spearman rank correlation coefficient was also used to analyze the relation between two different values. A level of P<0.05 was accepted as statistically significant. Fig. 1 shows the dose-response curves of SKG-IIIb cells 24, 48, and 96 h after the addition of various concentrations of EGF or TGF-α. The growth of SKG-IIIb cells was stimulated by the presence of 0.1 to 100 ng/ml of EGF or of 1 to 100 ng/ml of TGF-α in a concentration-dependent manner (P<0.01). Fig. 2 h incubation of tumor cells with 0.1 to 100 ng/ml of either growth factor resulted in a significant decrease of their DPD activity (P<0.01). In contrast, ThdPase and UrdPase activities of SKG-IIIb cells were stimulated by the presence of 10 to 100 ng/ml of EGF or TGF-α in a concentration-dependent manner (P<0.01; Fig. 2, b, c, e and f) . Correlation between tumor cell growth, and DPD and PyNPase activities Fig. 3 shows SKG-IIIb cell growth and DPD, ThdPase and UrdPase activities 96 h after the addition of various concentrations of EGF or TGF-α. Regression analysis with the Spearman rank correlation coefficient on plots of tumor cell growth versus DPD activity showed a significant inverse correlation between them (P<0.01; Fig. 3, a and e) . On the other hand, the stimulatory effects of EGF or TGF-α on tumor cell growth correlated well with both ThdPase and UrdPase activities (P<0.01): the greater the cell growth, the higher the ThdPase and UrdPase activities (Fig. 3, b, c, f and g ). The correlation of DPD and ThdPase activities further suggested that there was an inverse relation (P<0.01) between these two parameters after a 96-h treatment of tumor cells with EGF or TGF-α (Fig. 3, d and h) . Enhancement of antiproliferative action of 5-FU by growth factors Next, we examined whether 5-FU selectively kills SKG-IIIb cells exposed to EGF and TGF-α. Fig. 4 shows the dose-response curves of SKG-IIIb cells 7 days after the addition of 0.001 to 0.1 µg/ml of 5-FU with growth factors. EGF and TGF-α enhanced the antiproliferative action of 0.001 to 0.01 and 0.001 to 0.05 µg/ml of 5-FU on the cells, respectively (P<0.05). 
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DISCUSSION
The best understood aspect of the cytotoxic action of 5-FU is the FdUMP-mediated inhibition of TS, the final enzyme of the de novo pathway that converts 2′-deoxyuridylate to thymidylate by reductive methylation. 23) Experimental studies performed on colorectal, breast, or head and neck cancer cells have shown that overexpression of TS protein or TS activity is associated with 5-FU resistance. 7, 24, 25) However, Etienne et al. 8) reported that there was no relation between tumoral TS activity and 5-FU responsiveness and that TS was not likely to be the main target for 5-FU in head and neck cancer. Although much attention has been paid to the 5-FU activation routes, increased expression of TS is not universally recognized as a determinant factor for 5-FU sensitivity. 26, 27) Moreover, there have been few reports on the role of PyNPase, the first and rate-limiting enzyme in the 5-FU anabolic pathway. 14, 15, 28) Since Naguib et al. 29) first reported that DPD activity was high in the human liver and variable in tumors, the role of 5-FU catabolism at the cellular target level has been of interest. Tumoral DPD activity appears to be a promising predictor of 5-FU sensitivity. [7] [8] [9] [10] The DPD activity in human tumors seems to be highly variable: it ranged from 13 to 193 pmol/min/mg protein in biopsy specimens of 63 head and neck tumors 8) and from 28 to 207 pmol/min/mg protein in surgical specimens of 60 colorectal tumors. 30) However, data on tumoral DPD activity are limited, and the regulatory mechanisms determining DPD activity in human tumors are not fully understood.
Our present results demonstrate that tumoral DPD and PyNPase activities are regulated by growth factors and influence the 5-FU sensitivity of the tumor cells. The treatment of human uterine cervical carcinoma SKG-IIIb cells with EGF or TGF-α resulted in a concentrationdependent increase in tumor cell growth and PyNPase activity, whereas tumoral DPD activity was inhibited by the presence of these growth factors, again in a concentration-dependent manner. Stimulatory effects of EGF and TGF-α on tumor cell growth correlated well with PyNPase activity; however, there was an inverse relation between tumor cell growth and DPD activity. We observed that these growth factors stimulate the first, rate-limiting enzyme activity in 5-FU anabolism and inhibit that in 5-FU catabolism, leading to enhancement of the antiproliferative action of 5-FU at achievable therapeutic levels. EGF and TGF-α, tumor environmental factors, may act as potential intrinsic regulators of DPD and PyNPase activities that affect 5-FU sensitivity in individual tumors.
Previous researchers have hypothesized that DPD activity may be controlled by mechanisms related to tumor growth. [31] [32] [33] Queener et al. 31) demonstrated that DPD activity in rat hepatomas decreased in parallel with the increase in tumor growth rate. In contrast, Williams and Tuchman 32) reported that DPD activity in mouse neuroblastoma cells increased during culture, whereas thymidine kinase activity decreased markedly. Takechi et al. 33) observed time-dependent increases in DPD activity during the growth of human fibrosarcoma HT-1080 cells and human pancreatic carcinoma MIAPaCa-2 cells in cultures. The inverse relation between tumor cell growth and DPD activity in our study is consistent with the change of DPD activity in rat hepatomas during tumor growth. Generally, proliferating cells are much more sensitive to anticancer agents than nonproliferating cells are. In the case of 5-FU treatment, the antitumor activity of 5-FU has been found to be higher in growing small tumors than in stable large tumors in murine colon carcinomas.
34) The present results may provide a partial explanation: decreased DPD and increased PyNPase activities during tumor cell growth . Twenty-four hours after plating, cells were exposed to various concentrations of 5-FU. After further incubation for 7 days with growth factors, cell viability was evaluated by MTT assay. The relative percentages of cell growth compared to controls in the absence of EGF or TGF-α ( ) and in the presence of 10 ( ) and 100 ( ) ng/ ml of EGF or 10 ( ) and 100 ( ) ng/ml of TGF-α were plotted. Each point represents the mean of triplicates. may allow proliferating tumor cells to be more sensitive to 5-FU because of decreased degradation and increased activation of 5-FU.
Inflammatory cytokines, such as TNF α, IL-1α, and INF γ, that upregulate the expression of type-IV collagenase and PyNPase 14, 15) have been detected in various human and mouse tumor tissues. 13) Some of them are reported to enhance the metastatic potential of tumor cells in either in vitro or in vivo tumor models. 15, 35, 36) In addition, factors that downregulate cytokine expression, such as indomethacin, suppress metastasis. 37) Therefore, these tumor environmental factors would enhance the metastatic ability of tumor cells by upregulating type-IV collagenase activity, and 5-FU as well as 5′-dFUrd might inhibit metastasis by selectively killing such tumor cells due to the high PyNPase activity. We previously demonstrated that EGF and TGF-α also upregulate invasive activity and proteinase expression of cervical, endometrial and ovarian carcionoma cells. 16, 17) Our present results have revealed that these growth factors suppress tumoral DPD activity, thereby making tumor cells more sensitive to 5-FU. Moreover, it has been reported that INF α can induce a marked increase in PyNPase and a decrease in DPD activity. 28, 38) Fluoro-pyrimidines may be effective against tumor cells with high invasive and metastatic potential because of low DPD and high PyNPase activities under the influence of various tumor environmental factors that upregulate the invasive phenotype of the cells. The relation between the expression of cytokines and growth factors in tumor tissues and the anti-metastatic action of 5-FU and 5′-dFUrd should be further elucidated in in vivo tumor models.
